Novo Nordisk Stock Surges 6% After It Raises 2026 Outlook On Obesity Drug Sales

Novo lifted its full-year forecast for the second time in three months, though reported operating profit fell on DKK 8.7 billion of non-cash impairments.

Share
Novo Nordisk Stock Surges 6% After It Raises 2026 Outlook On Obesity Drug Sales

Novo Nordisk shares climbed 6.37% to $42.75 in Wednesday trading, as of 10:24 a.m. ET, adding about $11 billion in market value after the Danish drugmaker raised its 2026 outlook for the second time in three months. A CFO departure was announced alongside the results.

A forecast lifted again

Novo now expects growth of -2% to +2% at constant exchange rates for both adjusted sales and operating profit, up from -6% to 0% on August 4.

Adjusted operating profit reached DKK 31,720 million, up 27% at constant rates. Obesity franchise revenue grew 22% to DKK 26,146 million on that basis.

Impairments of DKK 8.7 billion, all non-cash, dragged reported operating profit down 9%.

The Wegovy pill sold DKK 5.4 billion in the third quarter, the first full quarter of its rollout in the markets where it has launched, the company said.

The maker of Ozempic and Wegovy

Novo Nordisk is a Denmark-based company that makes prescription drugs for obesity, diabetes and rare diseases, including the GLP-1 medicines Ozempic, Wegovy and Rybelsus. Ozempic, its top seller, had global sales of more than DKK 127 billion in 2025.

The shares were on pace for their biggest one-day gain since April 24, when they rose 6.9%. Even so, they were down about 21% year to date as of Tuesday's close, while the S&P 500 was up about 11%. The stock sat 37% below its highest close of the past year, set on January 26, as investors questioned whether consumer uptake of the Wegovy pill was slower than hoped.

The company's market value stood at $188.6 billion in Wednesday trading.

2027 guidance waits until February

CEO Mike Doustdar said Novo will give 2027 guidance only in February, after flagging U.S. list price cuts starting in January.

The next marker is February, when Novo has said it will issue its 2027 guidance.

Sources

More on Novo Nordisk

All Novo Nordisk (NVO) coverage →